Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 6, 2004, Pages 519-526

  Chan, Kin Tak ^a   Lung, Maria Li ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Doxorubicin; Drug resistance; Liver cancer; P glycoprotein; p53 mutation

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MUTANT PROTEIN; PACLITAXEL; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG UPTAKE; EXPRESSION VECTOR; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MUTATION; P-GLYCOPROTEIN; PACLITAXEL; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 2542424899     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0767-4     Document Type: Article

References (38)

1. Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55:891-903
2. Ince N, Wands JR (1999) The increasing incidence of hepatocellular carcinoma. N Engl J Med 340:782-798
3. Chen MF, Hwang TL, Jeng LB, Jan YY, Wang CS, Chou FF (1989) Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 124:1025-1028
4. Leung WT, Johnson PJ (2001) Systemic therapy for hepatocellular carcinoma, Semin Oncol 28:514-520
5. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
6. Lee TKW, Lau TCM, Ng IOL (2002) Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 49:78-86
7. Borbe R, Rieger J, Weller M (1999) Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. Cancer Chemother Pharmacol 44:217-227
8. Bush JA, Li G (2002) Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 98:323-330
9. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 83:4538-4542
10. Yusa K, Tsurio T (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49:5002-5006
11. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187: 111-116
12. Levine AV (1997) p53, the cellular gatekeeper for growth and division. Cell 88:3323-3331
13. Cadwell C, Zambetti GP (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30
14. Zhan Q, Antinore MJ, Wang, XW, Carrier F, Smith ML, Harris CC, Fornace AJ (1999) Association with Cdc-2 and inhibition of Cdc2/Cylin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18:2892-2900
15. Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin KH, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805
16. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
17. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutation in the p53 gene of human tumors and cell-line: updated compilation. Nucleic Acids Res 24:141-146
18. Blandino G, Levine A, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485
19. Rotter V, Sigal A (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788-6793
20. Lin Y, Shi CY, Li B, Soo BH, Mohammed-Ali S, Wee A, Oon CJ, Mack POP, Chan SH (1996) Tumor suppressor p53 and Rb genes in human hepatocellular carcinoma. Ann Acad Med Singapore 25:22-30
21. Patel VA, Dunn MJ, Sorokin A (2002) Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277:38915-38920
22. Tsang WP, Chau SPY, Fung KP, Kong SK, Kwok TT (2003) Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 51:161-166
23. Mates D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 20:4163-4172
24. Aurelio OS, Kong XT, Gupta S, Stanbridge EJ (2000) P53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 20:770-778
25. Muller M, Wider S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR. Stremmel W, Oren M, Krammer PH (1998) P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drug. J Exp Med 11:2033-2045
26. Ng IOL, Liu CL, Fan ST, Ng M (2000) Expression of P-glycoprotein in hepatocellular carcinoma: a determinant of chemotherapy response. Am J Clin Pathol 113:355-363
27. Moriki T, Takahashi T, Tanioka F, Yamane T, Hara H (1995) Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. Pathol Res Pract 191:1122-1132
28. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV (1994) Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71-77
29. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD (2001) Mutant p53 cooperates with ETS and selectively upregulates human MDR1 not MRP1. J Biol Chem 276:39359-39367
30. Strauss BE, Haas M (1995) The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 protein. Biochem Biophys Res Commun 217:333-340
31. Goldsmith ME, Gudas JM, Schneider E, Cowan KH (1995) Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 270:1894-1898
32. Chin KV, Ueda K, Pastan I, Gottesman MM (1992) Modulation of activity of the promoter of the human Mdr1 gene by Ras and p53. Science 255:459-462
33. Strauss BE, Shivakumar C, Deb SP, Deb S, Haas M (1995) The MDR1 downstream promoter contains sequence-specific binding sites for wild type p53. Biochem Biophys Res Commun 217:825-831
34. Kopnin BP, Stromskaya TP, Kondratov RV, Ossovskaya VS, Pugacheva EN, Rybalkina EY, Khokhlova OA, Chumakov PM (1995) Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Oncol Res 7:299-306
35. Fronza G, Inga A, Monti P, Scott G, Campomenosi P, Menichini P, Ottaggio L, Viaggi S, Burns P, Gold B, Abbondandolo A (2000) The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts. Mutat Res 462:293-301
36. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappus P, Sappino AP, Limacher JM, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92:3963-3967
37. Chan KT, Hsieh DPH, Lung ML (2003) In vitro aflatoxin B1-induced p53 mutation. Cancer Lett 199:1-7
38. Luo D, Cheng SCS, Xie H, Xie Y (1999) Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to Bcl-2 protein level. Tumor Biol 20:331-340